ReviewBioMed research international2014
Targeting the glutamatergic system to treat pathological gambling: current evidence and future perspectives.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Pharmacological interventions for the treatment of disordered and problem gambling.The Cochrane database of systematic reviews · 2022Pooled it
- Pharmacological Treatments for Disordered Gambling: A Meta-analysis.Journal of gambling studies · 2019Pooled it
- Altered long-range temporal correlations in delta oscillatory amplitude dynamics in gambling disorder.European archives of psychiatry and clinical neuroscience · 2026Article
- Off-label and investigational drugs in the treatment of gambling disorder: a critical review.Frontiers in pharmacology · 2026Review
- Aberrant glutamatergic systems underlying impulsive behaviors: Insights from clinical and preclinical research.Progress in neuro-psychopharmacology & biological psychiatry · 2024Review
- Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System.Drug safety · 2024Article
- The Potential of N-acetyl Cysteine in Behavioral Addictions and Related Compulsive and Impulsive Behaviors and Disorders: a Scoping Review.Current addiction reports · 2022Article
- Article
- Caudate nucleus volume mediates the link between glutamatergic neurotransmission and problematic smartphone use in youth.Journal of behavioral addictions · 2021Article
- Differential effects of glutamate N-methyl-D-aspartate receptor antagonists on risky choice as assessed in the risky decision task.Psychopharmacology · 2021Article
- Effects of 5-HTPsychopharmacology · 2020Article
- Maladaptive consequences of repeated intermittent exposure to uncertainty.Progress in neuro-psychopharmacology & biological psychiatry · 2020Review
- What drugs modify the risk of iatrogenic impulse-control disorders in Parkinson's disease? A preliminary pharmacoepidemiologic study.PloS one · 2020Article
- Expression of NMDA receptor subunits in human blood lymphocytes: A peripheral biomarker in online computer game addiction.Journal of behavioral addictions · 2018Article
- Gambling disorder: a side effect of an off-label prescription of baclofen-literature review.BMJ case reports · 2017Review
- Review
- Allostasis as a conceptual framework linking bipolar disorder and addiction.Frontiers in psychiatry · 2014Review
- Effects of NMDA receptor antagonists on probability discounting depend on the order of probability presentation.Pharmacology, biochemistry, and behaviorArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathological gambling or gambling disorder has been defined by the DSM-5 as a behavioral addiction. To date, its pathophysiology is not completely understood and there is no FDA-approved treatment for gambling disorders. Glutamate is the principal excitatory neurotransmitter in the nervous system and it has been recently involved in the pathophysiology of addictive behaviors. In this paper, we review the current literature on a class of drugs that act as modulating glutamate system in PG. A total of 19 studies have been included, according to inclusion and exclusion criteria. Clinical trial and case series using glutamatergic drugs (N-acetylcysteine, memantine, amantadine, topiramate, acamprosate, baclofen, gabapentin, pregabalin, and modafinil) will be presented to elucidate the effectiveness on gambling behaviors and on the related clinical dimensions (craving, withdrawal, and cognitive symptoms) in PG patients. The results have been discussed to gain more insight in the pathophysiology and treatment of PG. In conclusion, manipulation of glutamatergic neurotransmission appears to be promising in developing improved therapeutic agents for the treatment of gambling disorders. Further studies are required. Finally, we propose future directions and challenges in this research area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.